Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Nemtabrutinib With or Without Diltiazem in Healthy Participants
NCT07232589Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nemtabrutinib in hematological malignancies (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Infinity, Maximum Plasma Concentration and 5 more. Started Dec 2025; status: completed.
02
Drugs
nemtabrutinib
03
Conditions
hematological malignancies
Beyond the preview
Go deeper on NCT07232589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07232589.